For anyone who has had a direct or indirect personal encounter with cancer or disease, which is almost everyone, the momentum around the promise of precision medicine is both significant and palpable.
A solution in a disruptive technology.
A new-to-market class of disruptive testing technologies now allow simultaneous detection of dozens of biomarkers at single-cell resolution integrated with morphological and spatial context and are designed to enable the next generation of precision medicine discoveries. Intersect Diagnostics aims to be the leading CRO supporting biopharma companies in unlocking the biomarker signatures for their drug development programs. Through design, optimization, validation, and deployment of proprietary assays on these new instruments, our goal is to help advance drug development candidates toward regulatory approval.